

Table EU Approved biosimilars by molecule August 2020

(not available in all EU-countries) (status September 08, 2020; 62 products)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Amsparity, Halimatoz, Hefiya, Hulio, Hyrimoz, Idacio, Imraldi
bevacizumab	Avastin	MVasi, Zirabev; Positive opinion: Aybintio, Equidacent
Enoxaparine	Clexane	Inhixa
Epoetine alfa	Epex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi, Nepexto
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin Aspart	Novo Rapid	Insulin Aspart Sanofi
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Cegfila, Fulphila, Grasustek, Pelgraz, Pelmeg, Udenyca, Ziextenzo
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Ruxience, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa; Positive opinion: Livogiga, Qutavina.
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac

Source: EMA website

https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar

Accessed: September 08, 2020

For a comparison with US/FDA (January 2020) see:

<https://www.biosimilarsip.com/2020/06/09/biosimilar-approvals-stall-during-covid-19-pandemic-but-the-pipeline-grows/>

FDA approved biosimilars (status June 3, 2020)

<https://biosimilarsrr.com/us-biosimilar-filings/>

10 Biosimilar-products in the licensing pipeline at EMA (Status: 6/8/2020).

Adalimumab (1x); Bevacizumab (4x), insulin aspart (1x), Insulin Human (rDNA) 1x; pegfilgrastim (2x), trastuzumab (1x).